Janssen Research & Development, Llc

This study tested whether combining two drugs (guselkumab and golimumab) works better than one drug alone for active psoriatic arthritis. It involved 91 adults whose arthritis was not well controlled by previous TNF-alpha therapy. The main goal was to see if more people achieved …

This study tested whether adding nipocalimab to certolizumab works better than certolizumab alone for people with active rheumatoid arthritis who had not improved with other advanced treatments. 103 adults with moderate to severe RA took part. The main goal was to measure changes…

This study tested a gene therapy called AAV5-RPGR for people with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. The trial included 105 participants aged 3 and older. The main goal was to see if the treatment improved their ability to navigate a maz…

This study tested a drug called golimumab in 130 children with active juvenile idiopathic arthritis that did not improve with methotrexate. The drug is given through a vein and works by blocking a protein that causes inflammation. The main goal was to see how the drug moves throu…

This study tested whether adding daratumumab to standard chemotherapy (CyBorD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. 416 adults took part. The goal was to see if the combinat…

This study tested a drug called niraparib in 289 men with advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. Only men with certain DNA repair gene changes were included. The goal was to see if niraparib could shrink tumo…

This study tested a new combination of drugs (daratumumab, lenalidomide, and dexamethasone) in 45 people with multiple myeloma that had come back or stopped responding to treatment. The main goal was to see if the combination was safe and how many patients saw their cancer shrink…

This early-stage study tested a new drug called JNJ-74856665 in 153 people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal was to find safe doses and check for side effects. The drug works by blocking a protein that cancer cells need to grow. T…

This early-stage study tested a new drug called JNJ-75348780 in 147 people with two types of blood cancer (non-Hodgkin lymphoma and chronic lymphocytic leukemia) that had come back or stopped responding to other treatments. The drug is a special antibody designed to help the immu…

This study tested whether adding daratumumab to standard treatment (lenalidomide and dexamethasone) helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. The trial included 737 adults who were not healthy enough for a stem cell transpl…

This study tested a new drug, nipocalimab, against a placebo in 228 adults with active systemic lupus erythematosus (SLE). The goal was to see if nipocalimab could better control lupus disease activity, such as reducing skin rashes and joint pain, without worsening other symptoms…

This study followed 42 people who had already received a gene therapy for X-linked retinitis pigmentosa, an inherited eye disease that causes vision loss. The main goal was to check the treatment's long-term safety over up to 5 years. Researchers also looked at changes in functio…

This study tested the drug ustekinumab (STELARA) in 182 Chinese adults with moderate to severe Crohn's disease. The goal was to see if the drug could reduce symptoms and heal the gut lining over 52 weeks. Participants received the drug by IV and then injections, and researchers t…

This study tested whether adding apalutamide to standard hormone therapy after prostate removal surgery could delay cancer recurrence in 108 men with high-risk, non-spreading prostate cancer. The treatment aims to keep prostate-specific antigen (PSA) levels low, a sign that the c…

This study tested a drug called golimumab given through a vein (IV) in 208 adults with active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. The goal was to see if the drug could reduce symptoms like pain and improve function compared to a placeb…

This study tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that can turn into active cancer. The goal was to see which dose schedule works best to control the disease and prevent it from progressing. Participant…

This study tested a drug called ustekinumab in 101 children with moderate-to-severe Crohn's disease. The goal was to see if the drug could reduce symptoms and keep the disease under control. Children first received the drug through an IV, then some continued with injections to se…

This early-stage study tested a new drug called JNJ-64619178 in 114 adults with advanced cancers (like lymphoma, solid tumors, or myelodysplastic syndromes) that had not responded to other treatments. The main goal was to find the safest dose and check for side effects. The drug …

This study tested a new drug called JNJ-77242113 in 252 adults with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. The goal was to see if the drug could reduce symptoms like diarrhea and bleeding better than a placebo. Participants took the …

This study tested a new medication, JNJ-77242113, for long-term control of moderate-to-severe plaque psoriasis. A total of 227 adults who completed a prior study took the drug for up to 36 weeks. The main goal was to see how many achieved at least 75% clearer skin. This treatment…

This study tested a combination of two drugs, ibrutinib and rituximab, against other standard treatments for people with mantle cell lymphoma that had come back or stopped responding to therapy. The main goal was to check safety and allow people who were benefiting to keep receiv…

This study tested the drug guselkumab in 213 people with skin of color who have moderate-to-severe plaque or scalp psoriasis. Participants received either the drug or a placebo for 16 weeks. The goal was to see if guselkumab could significantly clear psoriasis patches and reduce …

This study tested a new drug, JNJ-77242113, in 255 adults with moderate-to-severe plaque psoriasis. The goal was to see if different doses could improve skin symptoms by at least 75% after 16 weeks. Participants were randomly assigned to receive the drug or a placebo. The results…

This study looked for special markers in the blood that could help doctors find pulmonary hypertension (high blood pressure in the lungs) earlier. Over 900 people took part, and researchers compared the blood test results to the standard diagnostic procedure (right heart catheter…

This study tested whether a new vaccine against a serious E. coli infection (ExPEC9V) can be given at the same time as the high-dose flu shot in adults 65 and older. About 959 volunteers received either both vaccines together or separately to check if the immune response stays st…

This study tested a drug called aticaprant in 513 adults with major depression who also had moderate-to-severe loss of interest or pleasure (anhedonia) and whose current antidepressants weren't working well enough. Participants took either aticaprant or a placebo pill along with …

This study tested a drug called guselkumab against a placebo in 338 adults with moderate plaque psoriasis that also affects special areas like the scalp or nails. The goal was to see if the drug could clear or nearly clear the skin. Results showed guselkumab was more effective th…

This study looked at 545 people with major depressive disorder who also experience anhedonia (loss of interest or pleasure) and whose current antidepressants were not working well enough. Researchers aimed to understand their background, disease features, and what treatments they…